+ Filter
Loading...
Anti-GAA Recombinant Antibody Products
Anti-GAA Recombinant Antibody Products
CompareCan't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
More Infomation
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs provides a wide range of high-quality, GAA-targeted recombinant antibodies to help global customers with their research and discovery efforts. Our robust platforms provide unrivaled value and first-rate technical support, allowing our customers to achieve their scientific objectives with maximum efficiency and accuracy.
GAA: A Crucial Target in Metabolic Disease
Acid alpha-glucosidase, also known as acid maltase, is crucial for breaking down glycogen within lysosomes. Deficiency in this enzyme leads to the accumulation of glycogen in lysosomes, causing glycogen storage disease II (GSD2), or Pompe disease. This accumulation predominantly affects cells in vital organs and tissues such as the heart and skeletal muscles, leading to their degradation and potentially life-threatening complications. The critical role of GAA in GSD2 pathogenesis makes it a promising therapeutic target for the treatment of GSD2 and other related metabolic disorders.
Alternative Names
Glucosidase alpha, acid; acid alpha-glucosidase preproprotein; glycogen storage disease type II; 76 kDa lysosomal alpha-glucosidase; Glucoamylase; E430018M07Rik; acid alpha-glucosidase; acid maltase; EC 3.2.1.20; 70 kDa lysosomal alpha-glucosidase; Aglucosidase alfa; lysosomal alpha-glucosidase; Alpha-1,4-glucosidase; Amyloglucosidase; LYAG
Background
This gene encodes lysosomal alpha-glucosidase, which is essential for the degradation of glycogen to glucose in lysosomes. The encoded preproprotein is proteolytically processed to generate multiple intermediate forms and the mature form of the enzyme. Defects in this gene are the cause of glycogen storage disease II, also known as Pompe's disease, which is an autosomal recessive disorder with a broad clinical spectrum. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2016]
Protein class
Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins
Predicted location
Intracellular
Single cell type specificity
Cell type enhanced (Syncytiotrophoblasts, Cytotrophoblasts, Extravillous trophoblasts, Kupffer cells)
Immune cell specificity
Group enriched (non-classical monocyte, classical monocyte, intermediate monocyte, myeloid DC, neutrophil, eosinophil)
Cell line specificity
Low cell line specificity
Molecular function
Glycosidase, Hydrolase
More Types Infomation
Anti-GAA Recombinant Antibody Products
Our goal is to elevate research and innovation by providing high-quality anti-GAA recombinant antibodies at an outstanding value, backed by superior technical assistance. Below, you'll find a selection of our most sought-after anti-GAA recombinant antibodies. Click on the link to discover the GAA antibodies that best meet your requirements.
| Cat. No. | Product Name | Target Species | Host Species | Applications |
| MOB-2426MZ | Recombinant Mouse Anti-Human GAA Antibody (clone 3C6) | Human | Mouse antibody | WB |
| MOR-1377 | Hi-Affi™ Rabbit Anti-GAA Recombinant Antibody (clone DS1377AB) | Human | Rabbit IgG | WB |
| MOB-2132z | Mouse Anti-GAA Recombinant Antibody (clone 44B11) | Human | Mouse IgG1, κ | WB, ELISA, IF, IHC, IP |
| ZG-0990F | Mouse Anti-GAA Recombinant Antibody (clone 43G7) | Human | Mouse IgG2a | IHC-P, WB |
Creative Quality Control
We are dedicated to driving innovation in biopharmaceutical research by providing top-tier products and outstanding customer service. Our stringent quality management protocols guarantee that our offerings exceed industry benchmarks, facilitating smoother drug development and adding substantial value for our customers.
Customer Reviews
Excellent
R***sHi-Affi™ Rabbit Anti-GAA Recombinant Antibody (clone DS1377AB) (MOR-1377)
I bought this Rabbit Anti-GAA Recombinant Antibody days ago and I employed this antibody to evaluate changes in GAA expression in GAA-KO mice after blocking treatment. I was thoroughly impressed by its outstanding sensitivity. Using this antibody, I was able to swiftly and effectively complete this segment of my research. Highly recommended!
7/Nov/2023
Excellent
Ste***eMouse Anti-GAA Recombinant Antibody (clone 43G7) (ZG-0990F)
I acquired this antibody product for Western Blot analysis to monitor alterations in GAA expression in cultured L6 myoblasts and GSD2 patient fibroblast cells following treatment with recombinant human GAA and tagged GAA. After incubating with samples at the suggested concentration, I observed a significant positive detection rate.
23/Feb/2024
Excellent
Qi***iMouse Anti-GAA Recombinant Antibody (clone 44B11) (MOB-2132z)
I utilized this antibody for my immunofluorescence experiments and found its purity to be exceptional. Following the recommended concentration for incubation, I observed no significant background interference, and the signal was remarkably clear and distinct. And, the product was delivered promptly and included a printed certificate of analysis detailing storage conditions and requirements.
12/Feb/2024
Anti-GAA Recombinant Antibody Production
Our state-of-the-art serum-free mammalian cell expression platform delivers end-to-end services, encompassing gene synthesis to large-scale anti-GAA recombinant antibody production. Leveraging over 5 years of process optimization, we ensure quick, economical, and scalable solutions. For high-demand quantities, our stable CHO cell line platform guarantees efficient production exceeding 5 grams, with a rapid and reliable turnaround.
Featured Anti-GAA Recombinant Antibody Production Platforms 
Fig.1Milligram-scale anti-GAA recombinant antibody production.
Fig.2 Gram-scale anti-GAA recombinant antibody production.
Anti-GAA Recombinant Antibody Modalities
Creative Biolabs delivers diverse anti-GAA recombinant antibody formats such as Fab, scFv, full-length, and many others to assist global customers in recombinant antibody research. For your unique research requirements, we also offer tailored solutions to ensure precision and reliability in results.
Fig.3 Full-Length Anti-GAA Recombinant Antibody Production and Modalities
GAA-Targeted Drug Information
Table 1. GAA-targeted drug information.
| Company | Highest Phase | Classification | Condition |
| Amicus Therapeutics (Originator) | Launched - 2023 |
Enzyme Replacement Therapy (ERT) Glycosidases Polypeptides, from 41 AA Recombinant proteins |
Pompe disease |
|
Astellas Gene Therapies (Originator) Audentes Therapeutics (Astellas Gene Therapies) |
Phase I/II |
Adeno-Associated Viral (A*V) Vectors Enzyme Replacement Therapy (ERT) Gene Therapy Glycosidases |
Pompe disease |
| Valerion Therapeutics (Originator) | Phase I/II |
Antibody-Derived Binding Proteins Enzyme Replacement Therapy (ERT) Fusion Proteins Glycosidases Polypeptides, from 41 AA |
Lafora disease Pompe disease |
|
Actus Therapeutics (Asklepios BioPharmaceutical) Asklepios BioPharmaceutical Duke University (Originator) |
Phase I/II |
Adeno-Associated Viral (A*V) Vectors Enzyme Replacement Therapy (ERT) Gene Therapy Glycosidases |
Pompe disease |
|
National Institutes of Health (NIH) (Originator) University of Florida (UF) (Originator) |
Phase I/II |
Adeno-Associated Viral (A*V) Vectors Enzyme Replacement Therapy (ERT) Gene Therapy Glycosidases |
Pompe disease |
| University of Florida (UF) (Originator) | Phase I |
Adeno-Associated Viral (A*V) Vectors Enzyme Replacement Therapy (ERT) Gene Therapy Glycosidases |
Pompe disease |
|
Astellas Gene Therapies (Originator) Audentes Therapeutics (Astellas Gene Therapies) |
IND Filed |
Adeno-Associated Viral (A*V) Vectors Enzyme Replacement Therapy (ERT) Gene Therapy Glycosidases |
Pompe disease |
| C*Nbridge Pharmaceuticals | Preclinical |
Adeno-Associated Viral (A*V) Vectors Enzyme Replacement Therapy (ERT) Gene Therapy Glycosidases |
Pompe disease |
|
Duke University (Originator) Genethon (Originator) Universite Pierre et Marie Curie (Originator) |
Biological Testing |
Adeno-Associated Viral (A*V) Vectors Enzyme Replacement Therapy (ERT) Enzymes Gene Therapy |
Glycogen storage disease |
| Callidus Biopharma | Biological Testing |
Enzyme Replacement Therapy (ERT) Fusion Proteins Glycosidases Polypeptides, from 41 AA Recombinant proteins |
Lysosomal storage diseases |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
To learn more about our anti-GAA recombinant antibody offerings, please feel free to contact us at your convenience. We look forward to collaborating with you and supporting your research endeavors.